CAPR PDUFA decision: a neutral outcome, -4.2%

On July 1, 2026, Capricor Therapeutics, Inc. reached its PDUFA decision. The result was a neutral outcome, and the stock moved -4.2% in the window around the event. It had already run -7.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.